| Name | Title | Contact Details |
|---|---|---|
Elizabeth Spinney |
Executive Director, R&D Counsel | Profile |
Ken Bair |
SVP & Head of R&D | Profile |
Linea Aspesi |
Senior Vice President and Chief Human Resources Officer | Profile |
Mary Wadlinger |
Senior Vice President of Human Resources | Profile |
Mary Wadlinger |
Senior Vice President of Corporate Affairs and Chief Human Resources Officer | Profile |
We are Salience Learning. We help solve life science’s most complex business challenges by delivering transformative learning experiences.
Mayne Pharma is a fast growing company, focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, with operations in Australia and the US. The Company has grown substantially and reflects the hard work and de...
Cosette Pharmaceuticals is a US based, diversified pharmaceutical company with a proven topicals and dermatology portfolio and a growing branded pharmaceuticals business. We are fully integrated, with a deep focus on internal R&D, high quality manufacturing standards and commercial sales excellence. We continue to diversify and expand through strategic partnerships, acquisitions and internal R&D. Our highly experienced leadership team are busy writing the next, most ambitious chapter of our story. Building on a 100+ year heritage, their shared vision of innovation will leverage the expertise of more than 350+ team members, and infrastructure to create remarkable new opportunities for the patients and physicians we serve every day.
Hoodia Products is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.